SUBSCRIBE
SUBSCRIBE
News   Drug Development

ERYtech Pharma: FDA Grants Orphan Drug Designation to GRASPA(R) for Treatment of Acute Lymphoblastic Leukemia

January 26, 2010 | 
1 min read

LYON, France & PHILADELPHIA--(BUSINESS WIRE)--ERYtech Pharma announces that FDA has granted an Orphan Drug Designation (ODD) for GRASPA®, the company’s lead product in Acute Lymphoblastic Leukaemia.

Clinical research Phase I Europe
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Businessman holding a dart aiming at the target - business targeting, aiming, focus concept. Art collage.
Infectious disease
Gilead, GSK-ViiV Move Ahead With Long-Acting HIV Options Following Early-Stage Readouts
March 12, 2025
 · 
2 min read
 · 
Tristan Manalac
Pictured: Entrance to Pfizer's office in Belgium
Breast cancer
Pfizer, Arvinas Post Mixed Late-Stage Breast Cancer Data for Closely Watched PROTAC Drug
March 11, 2025
 · 
2 min read
 · 
Tristan Manalac
Dollar banknote cut into pieces on a yellow background
Gene therapy
Roche Absorbs $2.4B Impairment in Overhaul of Spark Gene Therapy Unit
March 11, 2025
 · 
2 min read
 · 
Tristan Manalac
2D illustration showing scientists' hands editing a DNA strand
Gene editing
Beam’s Gene Editor Achieves ‘First Ever’ Genetic Correction in AATD
March 11, 2025
 · 
2 min read
 · 
Tristan Manalac